Theranos AI Diagnostic Fraud Trial

Thumbnail Image

The information displayed in the AIM should not be reported as representing the official views of the OECD or of its member countries.

Elizabeth Holmes, founder of Theranos, is on trial in the United States for allegedly defrauding investors and endangering patients by promoting AI-based blood testing technology that failed to perform as claimed. The malfunction and misrepresentation of the AI system led to financial and health-related harm.[AI generated]

Why's our monitor labelling this an incident or hazard?

The article explicitly involves an AI-related diagnostic technology developed by Theranos that failed to perform as claimed, leading to harm to patients (health harm) and investors (financial harm). The fraud allegations indicate misuse or misrepresentation of the AI system's capabilities, which directly caused harm. Hence, this event meets the criteria for an AI Incident due to the direct link between the AI system's malfunction/misuse and realized harm.[AI generated]
AI principles
AccountabilitySafetyRobustness & digital securityTransparency & explainability

Industries
Healthcare, drugs, and biotechnology

Affected stakeholders
ConsumersBusiness

Harm types
Physical (injury)Economic/Property

Business function:
Monitoring and quality control

AI system task:
Forecasting/prediction


Articles about this incident or hazard